Despite aggressive surgery and intensive chemotherapy, osteosarcoma recurs in ∼30--40% of patients initially diagnosed with non-metastatic disease ([@bib17]; [@bib18]; [@bib19]; [@bib15]; [@bib2], [@bib3]; [@bib22]). The outcome of patients with recurrent osteosarcoma is generally poor, with long-term survival rates of ∼20% ([@bib10]; [@bib13]; [@bib15]; [@bib1]). The most common site of relapse is the lung, and 50--75% of patients with recurrent osteosarcoma initially have lung involvement only ([@bib7]; [@bib8]; [@bib11]). Favourable prognostic indicators in recurrent disease include a longer disease-free interval from initial diagnosis to relapse, good histologic response to neoadjuvant chemotherapy in the primary tumour, a solitary lesion, and the ability to achieve a second complete surgical remission ([@bib10]; [@bib15]; [@bib11]; [@bib16]). For patients with pulmonary relapse, fewer nodules, unilateral involvement, complete surgical resection, and absence of pleural disruption are favourable prognostic factors ([@bib4]; [@bib15]; [@bib12]).

Although adjuvant chemotherapy is necessary for the treatment of newly diagnosed osteosarcoma, the role of chemotherapy in the treatment of recurrent disease is uncertain, especially for patients with solitary recurrent pulmonary metastasis. A study demonstrated that a disease-free interval \>12 months before developing osteosarcoma lung metastasis and complete surgical metastasectomy correlated with increased overall survival (OS; [@bib12]). Therefore, patients with recurrent osteosarcoma presenting with a single pulmonary nodule more than 1 year after diagnosis may represent a group of patients with favourable outcome for whom chemotherapy does not add benefit. The goals of this study were to characterise the clinical features and outcome of these patients and to evaluate the role of chemotherapy in this setting.

Patients and Methods
====================

After obtaining approval from the Institutional Review Board of each participating institution, a retrospective medical record review was conducted at three institutions: Memorial Sloan-Kettering Cancer Center, St Jude Children\'s Research Hospital (SJCRH), and the Children\'s Cancer Hospital of the University of Texas MD Anderson Cancer Center. Patients were considered eligible for this study if they were younger than 21 years of age at the time of initial diagnosis of non-metastatic high-grade osteosarcoma and had recurrence with only a single pulmonary metastasis more than 1 year after diagnosis that was confirmed by histology at the time of thoracotomy. Data collected included patient demographics, anatomic site of primary tumour, chemotherapy agents used during initial therapy, grade of histologic response to neoadjuvant therapy using the criteria described by [@bib14], time from diagnosis to recurrence, pulmonary nodule size, treatment at the time of recurrence, patient outcome, duration of follow-up, and cause of death. The date of relapse was defined as the time of thoracotomy for tumour removal.

Post-relapse survival (PRS) was defined as the time interval from the date of relapse to the date of death from any cause or the date of last contact for survivors. Post-relapse event-free survival (PREFS) was defined as the time interval from the date of relapse to the date of subsequent relapse or death from any cause or to the date of last contact for patients without subsequent events. PRS and PREFS were estimated using the method of Kaplan and Meier. Differences in distributions of PRS and PREFS among categorical variables were investigated using the exact log-rank test. Cox proportional hazards model was used to examine the association between continuous variables and outcome. Exact Wilcoxon rank-sum tests were used to examine the association between chemotherapy use at relapse with time to recurrence and nodule size.

Results
=======

Patient characteristics
-----------------------

A total of 39 patients satisfied the study inclusion criteria; their characteristics are summarised in [Table 1](#tbl1){ref-type="table"}. The median age at initial diagnosis was 14.6 years (range, 6.0--20.0 years). All patients were confirmed to have localised disease at the time of diagnosis. The femur was the most common primary site (*N*=22; 56%).

Treatment
---------

The patients were diagnosed between October 1977 and November 2002, and received different chemotherapy during this 25-year period ([Table 1](#tbl1){ref-type="table"}). For primary therapy, all patients had surgery and all but one received chemotherapy. The median number of active chemotherapeutic agents received was three (range, 0--4). For 31 patients with available data, the median time from date of diagnosis to date of definitive surgery was 2.3 months (range, 0--60 months), and 8 of these patients had surgery within 10 days of diagnosis. For the 31 patients who did not have upfront surgery as part of their primary treatment, histologic responses were grade I (*N*=3), grade II (*N*=13), grade III (*N*=5), and grade IV (*N*=5); progressive disease occurred before surgery in 2 patients and no data was available for 3 patients.

Recurrence and treatment at recurrence
--------------------------------------

All patients had a thoracotomy; the median time from diagnosis to thoracotomy date (recurrence date) was 2.5 years (range, 1.2--8.2 years; ([Figure 1](#fig1){ref-type="fig"}). The nodules occurred in the left (*N*=22) or right (*N*=17) lung. In 36 patients with available data, the median largest dimension of the pulmonary nodule was 1.5 cm (range, 0.5--18 cm). Twelve (31%) patients received chemotherapy at relapse.

Patient outcome
---------------

Twenty-three of 39 patients (59%) experienced a second recurrence, and 13 of these patients (57%) had a third recurrence or disease progression. [Table 2](#tbl2){ref-type="table"} shows the timing of recurrence for patients who experienced disease recurrence. Twenty-one of 39 patients (54%) were alive at the time of analyses. The median follow-up duration from initial diagnosis was 12 years (range, 1.8--22.1 years). The median follow-up duration from the date of thoracotomy for survivors was 7.7 years (range, 0.6--20.9 years). Eighteen patients had no evidence of disease and three were alive with disease. The remaining 18 patients died of disease (*N*=14) or other causes: acute myeloid leukaemia (*N*=1), brain aneurysm (*N*=1), sepsis (*N*=1), and unknown cause (*N*=1). The 5-year and 10-year estimates of PREFS were 33.0±7.5% and 33.0±9.6%, respectively, and of PRS 56.8±8.6% and 53.0±11.0%, respectively ([Figure 2](#fig2){ref-type="fig"}).

Prognostic factors
------------------

[Table 3](#tbl3){ref-type="table"} summarises the results of investigating various factors as predictors of PRS and PREFS. None of the factors investigated were found to be significantly predictive of PRS. When investigated as a continuous variable, there was no evidence that time from diagnosis to relapse was significantly predictive of PRS (*P*=0.123; hazard ratio, 0.75 (95% confidence interval, 0.53--1.08)). When investigated as a categorical variable (⩾1 year to \<2 years *vs* ⩾2 years to \<3 years *vs* ⩾3 years to \<4 years *vs* ⩾4 years after diagnosis), a trend was observed towards a positive predictive value for longer duration between diagnosis and relapse for PREFS (*P*=0.062), but not for PRS (*P*=0.31). When analysed as a continuous variable, nodule size was not significantly associated with PRS (*P*=0.80; hazard ratio, 0.98). When studied as a categorical variable, a trend was observed between size \<1.5 cm and improved PREFS (*P*=0.070), but not PRS (*P*=0.49). Chemotherapy at first relapse did not affect PREFS (*P*=0.84) or PRS (*P*=0.54). Further analysis was performed to investigate whether there was any selection bias for patients who received chemotherapy at relapse with respect to nodule size and time to recurrence. There was no statistically significant difference for time to recurrence and nodule size between patients who received chemotherapy and those who did not (*P*\>0.11).

Discussion
==========

In this study, we analysed the treatment and outcome of 39 patients treated at three major cancer centres for osteosarcoma that recurred as a single pulmonary metastasis more than 1 year after diagnosis. All patients had thoracotomy and about one third received chemotherapy. The 10-year PREFS and PRS were 33.0±9.6% and 53.0±11.0%, respectively. These survival estimates compare favourably with those of patients with first relapse of osteosarcoma in general (10-year PREFS, 12% and 10-year PRS, 17--18% [@bib15], [@bib16]). Our study confirms that patients with recurrent osteosarcoma presenting as a single pulmonary nodule more than 1 year after diagnosis represent a favourable group of patients who can be cured by surgery alone. The use of chemotherapy at first relapse did not improve outcome.

In a retrospective review of 576 patients with relapsed osteosarcoma by the Cooperative Osteosarcoma Study Group (COSS), 80% of patients had lung metastasis and 65% of patients had lung metastasis as the only site of recurrence ([@bib15]). Another review by the European Osteosarcoma Intergroup noted lung-only recurrence in 54% of the patients ([@bib11]). Although the long-term prognosis for patients with recurrent osteosarcoma remains poor, some progress has been made in identifying risk factors that can be used for patient stratification and tailoring salvage therapy. [@bib13] reported that for patients with initial pulmonary recurrence, the presence of solitary pulmonary nodules was associated with improved disease-free survival and OS. The COSS study demonstrated that bilateral pulmonary metastases and pleural disruption were poor prognostic factors ([@bib15]). [@bib16] reported that for patients with pulmonary relapse, unilateral disease and the presence of ⩽3 nodules were favourable clinical factors.

Surgical resection of pulmonary metastases, whenever feasible, has been long considered standard treatment ([@bib5], [@bib21], [@bib12]). Disease-free interval following metastasectomy appears to be important for survival in recurrent osteosarcoma in the lung; one study noted a 3% decrease in mortality associated with each additional month of disease-free interval ([@bib4]). Thoracotomy with wedge resection has been the preferred surgical approach for removal of lung nodules; a median sternotomy does not allow full exploration of the posterior pulmonary segments for nodules that may not have been radiologically evident. All patients in our study underwent thoracotomy for removal of the lung nodule. However, a recent study suggested that a minimally invasive approach to nodule removal with image-guided localisation, if needed, should be considered in patients with single pulmonary nodule because ipsilateral metastases are not likely to be found ([@bib9]).

The use of chemotherapy for patients with isolated pulmonary recurrence of osteosarcoma has been widely debated. One significant consideration for using a surgical-only treatment approach is to avoid the potential acute and late toxicities of chemotherapy. In the [@bib13] study, survival was superior among patients with pulmonary recurrence treated with surgery alone compared with patients treated with chemotherapy and surgery (47% *vs* 13%, *P*=0.005). For patients with isolated pulmonary recurrence who achieved a second complete remission of disease, a trend towards improved survival rates for patients treated with surgery alone approached statistical significance (45% *vs* 13%, *P*=0.08). However, the improved survival for patients treated with surgery alone likely reflects a biased use of chemotherapy in patients with incompletely resected disease. [@bib10] reported that PRS was positively influenced by the use of second-line chemotherapy in patients who did not have complete surgery, but not in patients who had complete surgery. In their subgroup analysis of patients with isolated pulmonary recurrence who had complete surgical remission, PRS was better in patients with two or fewer nodules and a relapse-free interval longer than 24 months. In the COSS study of the largest cohort of patients with recurrent osteosarcoma, the use of second-line chemotherapy, particularly chemotherapy with more than one agent, was associated with better OS for the entire cohort and for patients without second complete remission, but not for patients with second complete remission ([@bib15]). In patients who achieved a second complete remission, second-line chemotherapy positively correlated with event-free survival but not OS. In the SJCRH experience with 110 patients with relapsed osteosarcoma, the use of chemotherapy at first relapse was associated with improved PREFS only in patients without second complete remission, and was not associated with PRS ([@bib16]). Another study based on single institutional experience did not demonstrate a survival advantage for those patients who received chemotherapy compared with patients who only underwent surgical resection for first recurrence ([@bib8]). Analysis of our cohort did not reveal survival advantage with the use of chemotherapy. Thus, the lack of evidence for benefit from salvage chemotherapy and the relatively favourable outcome of patients with relapsed osteosarcoma presenting as a single pulmonary nodule support the use of surgery only for treating these patients.

Our study is limited by its retrospective nature and the small cohort size that may have affected our ability to further delineate whether some of the clinical prognostic factors would have reached statistical significance. Because our study included only patients who had a relapse more than 1 year after diagnosis and the median time to relapse was 2.5 years, we could not further ascertain whether patients who present with a solitary pulmonary nodule recurrence may in fact represent a subset of relapsed patients with longer duration of disease-free interval, a known good prognostic factor. In the COSS study, a correlation was noted between solitary site of relapse and longer interval to relapse ([@bib15]).

In conclusion, our multi-institutional study demonstrated that approximately half of the patients with recurrent osteosarcoma as a solitary pulmonary nodule more than 1 year after diagnosis were long-term survivors. Whether this improved outcome compared with that of patients with recurrent osteosarcoma in general could be related to low disease burden or favourable tumour biology remains to be determined. Our analyses did not reveal factors that help identify patients who are likely to survive or die, although there was a trend for improved outcome for those with smaller nodules or later relapse. It is hoped that clinical genomics or the ability to detect circulating sarcoma cells will help discern which patients will require further therapy in addition to surgery ([@bib6], [@bib20]). While the use of salvage chemotherapy did not confer a survival advantage in our study, perhaps novel therapies that are likely to be effective in the setting of minimal residual disease such as immunotherapy, will prove to be beneficial.
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###### Patient characteristics and initial treatment

  **Characteristic**                                   ***N***   **%**
  ---------------------------------------------------- --------- -------
  **Institution**                                                
  MSKCC                                                15        38.5
  SJCRH                                                14        35.9
  UTMDACC                                              10        25.6
  **Gender**                                                     
  Male                                                 23        59.0
  Female                                               16        41.0
  **Race**                                                       
  Caucasian                                            24        61.5
  Latino/hispanic                                      8         20.5
  Black                                                6         15.4
  Asian                                                1         2.6
  **Primary site**                                               
  Femur                                                22        56.4
  Tibia                                                12        30.8
  Humerus                                              2         5.1
  Ilium                                                2         5.1
  Radius                                               1         2.6
  **Number of chemotherapy agents**                              
  0                                                    1         2.6
  1                                                    0         0
  2                                                    12        30.8
  3                                                    16        41
  4                                                    10        25.6
  **Histologic response**[a](#t1-fn2){ref-type="fn"}             
  I                                                    3         9.7
  II                                                   13        41.9
  III                                                  5         16.1
  IV                                                   5         16.1
  PD                                                   2         6.5
  Data unavailable                                     3         9.7

Abbreviations: MSKCC=Memorial Sloan-Kettering Cancer Center; SJCRH=St. Jude Children\'s Research Hospital; UTMDACC=University of Texas MD Anderson Cancer Center; PD=progressive disease.

Data on 31 patients who received neoadjuvant chemotherapy before surgery.

###### Timing of recurrence

                                 ***N***    **Median**          **Range**
  ------------------------------ --------- ------------- -----------------------
  Time from diagnosis to RL1     39          2.5 years    1.2 years--8.2 years
  Time from thoracotomy to RL2   23         10.8 months   1.8 months--3.8 years
  Time from RL2 to RLPD3         13         5.2 months    1.6 months--5.9 years

Abbreviations: RL1=first relapse; RL2=second relapse; RLPD3=third relapse or disease progression.

###### Exploratory analyses of potential prognostic factors

                                           **PRS±s.e. (%)**   **PREFS**±**s.e. (%)**                                  
  ----------------------------------- ---- ------------------ ------------------------ ------ ----------- ----------- -----------
  **Age at diagnosis**                                                                                                
  \<16 years                          27   62.1±10.2          56.4±12.4                0.86   32.8±9.0    32.8±11.0   0.78
  ≥16 years                           12   46.3±13.9          46.3±19.6                       33.3±12.2   33.3±15.7    
  **Gender**                                                                                                          
  Female                              16   57.7±12.5          57.7±14.2                0.93   40.4±11.8   40.4±13.9   0.49
  Male                                23   55.9±11.2          49.7±15.8                       27.8±8.9    27.8±11.8    
  **Primary tumour site**                                                                                             
  Femur                               22   56.1±10.7          49.9±14.4                0.83   33.8±9.7    33.8±12.3   0.61
  Other bones                         17   58.2±13.3          58.2±15.4                       31.9±10.7   31.9±13.2    
  **No. of active agents**                                                                                            
  \<3 active agents                   13   59.8±13.4          49.9±17.7                0.78   30.8±11.4   30.8±14.8   0.95
  ≥3 active agents                    26   55.5±10.7          55.5±13.1                       34.3±9.3    34.3±11.3    
  **Histologic response**                                                                                             
  Grade I or II or PD                 18   46.4±12.8          46.4±15.2                0.73   20.0±8.9    20.0±10.3   0.80
  Grade III or IV                     10   52.5±16.2          52.5±25.6                       30.0±12.5   30.0±17.7    
  **Time to thoracotomy**                                                                                             
  ≥1 year to \<2 years                15   43.1±13.3          43.1±14.5                0.31   22.2±9.8    22.2±9.8    **0.062**
  ≥2 years to \<3 years               11   62.5±15.6          46.9±17.1                       18.2±9.5    18.2±11.6    
  ≥3 years to \<4 years               6    50.0±17.7          50.0±25.0                       33.3±15.7   33.3±19.2    
  ≥4 years                            7    83.3±13.9          83.3±19.6                       85.7±13.2   85.7±18.7    
  **Time to thoracotomy**                                                                                             
  \<18 months                         8    42.9±16.2          42.9±16.2                0.97   30.0±14.5   30.0±14.5   0.93
  ≥18 months                          31   60.3±9.5           55.2±13.1                       33.7±8.3    33.7±11.2    
  **Site of pulmonary nodule**                                                                                        
  Left lung                           22   54.7±11.1          54.7±16.5                0.95   34.1±9.8    34.1±13.8   0.66
  Right lung                          17   58.9±12.6          51.6±13.6                       31.5±10.6   31.5±11.7    
  **Size of Pulmonary Nodule**                                                                                        
  \<1.5 cm                            17   59.2±12.6          50.8±14.5                0.49   44.1±11.7   44.1±13.5   **0.070**
  ≥1.5 cm                             19   57.7±11.9          57.7±16.8                       28.5±9.8    28.5±13.9    
  **Chemotherapy at first relapse**                                                                                   
  Yes                                 12   50.9±14.6          50.9±17.8                0.54   37.5±13.3   37.5±17.1   0.84
  No chemotherapy                     27   59.0±10.1          54.1±13.0                       31.2±8.6    31.2±10.6    

Abbreviations: PRS=post-relapse survival; PREFS=post-relapse event-free survival; PD=progressive disease
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